TransCode: Preclinical Data Supports Therapeutic Potential Of TTX-MC138 In Metastatic Breast Cancer

(RTTNews) - TransCode Therapeutics Inc. (RNAZ) announced publication in Cancer Nanotechnology of preclinical data supporting therapeutic potential of TTX-MC138(MN-anti-miR10b) in metastatic breast cancer.

In Thursday pre-market trade, RNAZ was trading at $3.09 up $0.47 or 17.94%.

The study confirmed the biodistribution of TTX-MC138 in models of metastatic cancer, supporting TransCode's TTX platform for delivery of RNA targeted therapy to metastatic solid tumors.

The company looks forward to its Phase 0 study which has the potential to establish clinical proof-of-concept for this therapy.

TransCode expects to file an exploratory investigational new drug (eIND) application for TTX-MC138 in the first quarter of 2022 to support a Phase 0 study in patients with metastatic cancer.

Under an eIND, FDA approval may be obtained more quickly and at lower cost than with a traditional IND for therapeutic agents.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More